Classifications: hormone; gonadotropin-releasing hormone antagonist; Therapeutic:gonadotropin-releasing hormone
Pregnancy Category: X
0.25 mg, 3 mg injection
Cetrotide is a luteinizing hormone-releasing hormone (LHRH) antagonist.
It prevents premature LH surges in patients undergoing controlled ovarian hyperstimulation for assisted reproduction.
Treatment of infertility as part of an assisted reproduction program.
Hypersensitivity to cetrorelix, extrinsic peptide hormones, mannitol, gonadotropin-releasing hormone analogs; primary ovarian
failure; renal failure; pregnancy (category X); known or suspected pregnancy; lactation.
Hepatic insufficiency; polycystic ovary syndrome.
Route & Dosage
Adult: SC 0.25 mg/d during early to mid follicular phase of the cycle (stimulation day 5 or 6) following the initiation of FSH or
3 mg as a single dose is administered when the serum estradiol level is indicative of an appropriate stimulation response,
usually on FSH stimulation day 7 (range day 59). If HCG has not been administered within 4 d after the injection of
3 mg, then 0.25 mg should be administered once daily until HCG administration
- Reconstitute the 0.25 or 3 mL vial with 1 or 3 mL, respectively, of sterile water for injection.
- Inject into lower abdominal wall following reconstitution. Rotate injection sites.
- Store the 3 mg dose at room temperature, 15°30° C (59°86° F). Store the 0.25 mg dose in the
Adverse Effects (≥1%)CNS:
Nausea, vomiting, abdominal pain. Endocrine:
Hot flashes. Skin:
Pruritus at injection site. Urogenital:
Ovarian enlargement, ovarian hyperstimulation syndrome
, pelvic pain.
InteractionsDrug: Cimetidine, methyldopa, metoclopramide, reserpine, phenothiazines
may interfere with fertility efforts. Herbal: Black cohosh, DHEA
may antagonize fertility efforts.
85% absorbed from SC injection site. Peak:
12 h. Metabolism:
Metabolized by peptidases. Elimination:
24% in urine, 510% in bile. Half-Life:
62 h after single dose, 20 h after multiple doses.
Assessment & Drug Effects
- Lab test: Monitor routine blood chemistries.
- Monitor weight and report development of edema and/or shortness of breath.
Patient & Family Education
- Contact physician immediately for any of the following: Abdominal or stomach pain, persistent or severe nausea, vomiting
or diarrhea; decreased urination; pelvic pain; moderate to severe bloating, rapid weight gain; shortness of breath; swelling
of lower legs.
- Understand that hot flashes are a common side effect of this drug.